Not an eMediNexus Member?
Trilaciclib became the first drug in its class to be approved by the U.S. Food and Drug Administration for reducing the incidenc ...MORE
Rates of cancer were reported to rise by 30% from 1973 to 2015 in adolescents and young adults (AYAs) (aged 15-39 years) in the ...MORE
In patients taking adjuvant pembrolizumab for stage III melanoma, immune-related adverse events (irAE) are associated with longe ...MORE
The incidence of melanoma is remarkably reduced in patients with obesity after bariatric surgery.
A new research suggests that a high body mass index (BMI) which is usually linked to diseases like diabetes and other cardiovasc ...MORE
A new study sheds light on one potential health benefit of exercise: a lower risk of certain cancers.